Skip to main content

Table 4 Univariate Cox regression analysis for HER2 and TOP2A adjusted for treatment

From: HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy

 

Disease-free survival

Overall survival

 

HR

95% C.I.

Wald's p

HR

95% C.I.

Wald's p

HER2 (CISH)

      

   Non-amplified

1

  

1

  

   Amplified

1.55

1.01-2.39

0.045

1.62

0.98-2.66

0.060

HER2 (mRNA)

      

   Low

1

  

1

  

   High

1.89

1.29-2.79

0.001

1.91

1.21-3.02

0.005

HER2 (IHC)

      

   0-1+

1

  

1

  

   2+

1.61

0.93-2.78

0.091

2.13

1.18-3.84

0.012

   3+

1.75

1.10-2.79

0.019

1.78

1.02-3.08

0.041

HER2 status

      

   Negative

1

  

1

  

   Positive*

1.57

1.04-2.39

0.033

1.68

1.04-2.72

0.034

TOP2A (CISH)

      

   Non-amplified

1

  

1

  

   Amplified

0.35

0.11-1.10

0.072

0.34

0.08-1.38

0.131

TOP2A (mRNA)

      

   Low

1

  

1

  

   High

1.45

1.01-2.10

0.046

2.34

1.46-3.73

< 0.001

TopoIIa (IHC)

      

   Negative

1

  

1

  

   Positive

1.37

0.90-2.10

0.145

1.55

0.93-2.60

0.094

HER2/TOP2A CISH

      

   All other

1

  

1

  

   Both amplified

0.17

0.2-1.20

0.075

0.25

0.04-1.80

0.17

HER2/TOP2A mRNA

      

   All other

1

  

1

  

   Both high

2.15

1.37-3.38

0.001

2.51

1.51-4.18

< 0.001

HER2/TopoIIa IHC

      

   All other

1

  

1

  

   Both positive

1.92

1.14-3.25

0.015

1.89

1.04-3.44

0.038

  1. * IHC 3+ or CISH amplified.
  2. There was no interaction between examined markers with treatment regimens (p > 0.05 for all interaction tests).